-
Abken H et al.
Tuning tumor-specific T-cell activation: a matter of costimulation?
Trends Immunol 2002;23:240-245.
-
Becker JC et al.
T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
J Exp Med 1996a;183:2361-2366.
-
Becker JC et al.
Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
Proc Natl Acad Sci USA 1996b;93:2702-2707.
-
Boon T et al.
Tumor antigens recognized by T lymphocytes.
Annu Rev Immunol 1994;12:337-65.
-
Carter P.
Improving the efficacy of antibodybased cancer therapies.
Nat Rev Cancer 2001;1:118-129.
-
Chapman PB et al.
Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
Cancer Immunol Immunother 1994;39:198-204.
-
Cheresh DA et al.
Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells.
Proc Natl Acad Sci USA 1984;81:5767-5771.
-
Clark M.
Antibody humanization: a case of the ‘Emperor's new clothes'?
Immunol Today 2000;21:397-402.
-
Cochlovius B et al.
Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments.
Int J Cancer 1999;81:486-493.
-
Colucci F, Caligiuri MA, Di Santo JP.
What does it take to make a natural killer?
Nat Rev Immunol 2003;3:413-425.
-
Dippold WG et al.
Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues.
Cancer Res 1985;45:3699-3705.
-
Dippold WG et al.
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.
Proc Natl Acad Sci USA 1980;77:6114-6118.
-
Dranoff G.
GM-CSF-secreting melanoma vaccines.
Oncogene 2003;22:3188-3192.
-
Egen, JG, Kuhns MS, Allison JP.
CTLA-4: new insights into its biological function and use in tumor immunotherapy.
Nat Immunol 2002;3:611-618.
-
Gillies SD et al.
Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.
Proc Natl Acad Sci USA 1992;89:1428-1432.
-
Green MC, Murray JL, Hortobagyi GN.
Monoclonal antibody therapy for solid tumors.
Cancer Treat Rev 2000;26:269-286.
-
Grosse-Hovest L et al.
Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
Int J Cancer 1999;80:138-144.
-
Hanai N, Nakamura K, Shitara K.
Recombinant antibodies against ganglioside expressed on tumor cells.
Cancer Chemother Pharmacol 2000;46 Suppl:13-17.
-
Hodi FS et al.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Proc Natl Acad Sci USA 2003;100:4712-4717.
-
Houghton AN, Gold JS, Blachere NE.
Immunity against cancer: lessons learned from melanoma.
Curr Opin Immunol 2001;13:134-140.
-
Hurwitz AA, Kwon ED, van Elsas A.
Costimulatory wars: the tumor menace.
Curr Opin Immunol 2000;12:589-596.
-
Kaminski MJ et al.
The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains.
J Biol Chem 1999;274:5597-5604.
-
King DM et al.
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
J Clin Oncol 2004;22:4463-4473.
-
Kirkwood JM et al.
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
Cancer 2000;88:2693-2702.
-
Koni PA et al.
Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice.
Immunity 1997;6:491-500.
-
Nakamura K et al.
Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
Cancer Immunol Immunother 2001;50:275-284.
-
Nasi ML et al.
Anti-melanoma effects of R4, a monoclonal antibody against GD3 ganglioside.
Melanoma Res 1997;27 Suppl 2:155-162.
-
Ohta S et al.
Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Cancer Immunol Immunother 1993;36:260-266.
-
Ortaldo JR et al.
Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
J Immunol 1987;138:3566-3572.
-
Phan GQ et al.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc Natl Acad Sci USA 2003;100:8372-8377.
-
Pukel CS et al.
GD 3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.
J Exp Med 1982:155;1133-1147.
-
Ramirez-Montagut T et al.
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
Oncogene 2003;22:3180-3187.
-
Reisfeld RA et al.
Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein.
Cancer Res 1996;56:1707-1712.
-
Rettig WJ, Old LJ.
Immunogenetics of human cell surface differentiation.
Annu Rev Immunol 1989;7:481-511.
-
Riedle S, Rosel M, Zoller M.
In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice.
Int J Cancer 1998;75:908-918.
-
Rohrbach P et al.
Therapeutic antibodies and antibody fusion proteins.
Biotechnol. Genet Eng Rev 2003;20:137-163.
-
Rosenberg SA.
Progress in human tumour immunology and immunotherapy.
Nature 2001;411:380-384.
-
Sanz L, Blanco B, Alvarez-Vallina L.
Antibodies and gene therapy: teaching old ‘magic bullets' new tricks.
Trends Immunol 2004;25:85-91.
-
Schrama D et al.
Targeting of lymphotoxinalpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.
Immunity 2001;14:111-121.
-
Scott AM et al.
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
J Clin Oncol 2001;19:3976-3987.
-
Shitara K et al.
A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
Cancer Immunol Immunother 1993;36:373-380.
-
Soiffer R et al.
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colonystimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
J Clin Oncol 2003;21:3343-3350.
-
Straten PT et al.
Activation of preexisting T cell clones by targeted interleukin 2 therapy.
Proc Natl Acad Sci USA 1998;95:8785-8790.
-
Sutmuller RP et al.
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
J Exp Med 2001;194:823-832.
-
Tivol EA et al.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Immunity 1995;3:541-547.
-
van Elsas A, Hurwitz AA, Allison JP.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
J Exp Med 1999;190:355-366.
-
van Elsas A et al.
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
J Exp Med 2001;194:481-489.
-
Waterhouse P et al.
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
Science 1995;270:985-988.
Bildatlas Hämatologie
Druckversion
ISSN: 2193-6021
Zum Seitenanfang